Tissue Repair Ltd
Tissue Repair Ltd is an Australia-based clinical-stage biopharmaceutical company engaged in the development of therapies for wound healing and tissue regeneration.
The business
Tissue Repair Ltd is an Australia-based clinical-stage biopharmaceutical company engaged in the development of therapies for wound healing and tissue regeneration. The Company’s business activities include the development of topical wound care products and regenerative therapies, supported by its proprietary Glucoprime technology platform. The Company is engaged in Phase III clinical trials in chronic wounds for its lead drug candidate Chronic wound treatment (TR-987), with a secondary focus on commercializing post-procedure cosmeceutical (TR Pro+) a post procedure topical gel to accelerate healing and improve skin quality following cosmetic and medical procedures. Its other applications of Glucoprime technology include the treatment of burns, an over the counter/pharmacy wound product, new bandage and scaffold products impregnated with Tissue Repair’s active pharmaceutical ingredient, veterinary products, among others.
Small Caps Research
No research on Tissue Repair Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise TRP based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.